[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Murphy et al., 2020 - Google Patents

Targeting focal adhesion kinase in cancer cells and the tumor microenvironment

Murphy et al., 2020

View HTML @Full View
Document ID
12493056117219672635
Author
Murphy J
Rodriguez Y
Jeong K
Ahn E
Lim S
Publication year
Publication venue
Experimental & molecular medicine

External Links

Snippet

Focal adhesion kinase (FAK) is an integrin-associated protein tyrosine kinase that is frequently overexpressed in advanced human cancers. Recent studies have demonstrated that aside from FAK's catalytic activity in cancer cells, its cellular localization is also critical …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Similar Documents

Publication Publication Date Title
Murphy et al. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment
Wilson et al. Oncogenic functions and therapeutic targeting of EphA2 in cancer
Mardinian et al. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy
Cowman et al. Revisiting the HIF switch in the tumor and its immune microenvironment
Dawson et al. Targeting FAK in anticancer combination therapies
Lytle et al. Stem cell fate in cancer growth, progression and therapy resistance
Kim et al. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Hu et al. Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy
Kim et al. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer
Xu et al. TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer
Schiewer et al. Dual roles of PARP-1 promote cancer growth and progression
Zhou et al. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
Shitashige et al. Traf2-and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth
Lemoine et al. Overcoming intrinsic resistance of cancer cells to CAR T-cell killing
Bertsch et al. Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2
Lindner et al. α2-Macroglobulin inhibits the malignant properties of astrocytoma cells by impeding β-catenin signaling
Dominguez et al. Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
Press et al. Role for polo-like kinase 4 in mediation of cytokinesis
Paduano et al. T-cell leukemia/lymphoma 1 (TCL1): an oncogene regulating multiple signaling pathways
Heidel et al. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity
Barat et al. Gamma-Secretase Inhibitor IX (GSI) impairs concomitant activation of notch and wnt-Beta-Catenin pathways in CD44+ gastric cancer stem cells
Palisoul et al. Inhibition of the receptor tyrosine kinase AXL restores paclitaxel chemosensitivity in uterine serous cancer
Woolf et al. Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy
Zhu et al. Synthetic lethal strategy identifies a potent and selective TTK and CLK1/2 inhibitor for treatment of triple-negative breast cancer with a compromised G1–S checkpoint
Dufour et al. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer